{"certainAgreement":{"otherDetails":"PI's are required to abide by the sponsor's publication guidelines which require review by coauthors and subsequent review and approval by the sponsor.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The 200 mg/m\\^2 treatment arm in the phase I component of the study did not open. Outcome measures are categorized as the phase I or phase II study component, but phase I patients at corresponding dose level are included in the phase II analyses."},"pointOfContact":{"email":"seiferheldw@nrgoncology.org","organization":"NRG Oncology","title":"Wendy Seiferheld, M.S."}}